Novartis unveils new focused strategy
Transformation to pure-play Innovative Medicines company nears completion
Transformation to pure-play Innovative Medicines company nears completion
The second day of Arogya Manthan 2022 had panel discussions with eminent thought leaders from relevant public and private sector organizations
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
Philips Foundation and RAD-AID International leverage Philips’ expertise in mobile ultrasound services to improve access to virtual care in hard-to-reach areas
Subscribe To Our Newsletter & Stay Updated